Fidelity SPDR Advertisement
Home > Boards > US OTC > Delisted > GTC Biotherapeutics (fka GTCB)

Re: Expiration dates of Rituxan patents

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
DewDiligence Member Profile
Member Level 
Followed By 496
Posts 82,576
Boards Moderated 24
Alias Born 09/05/02
160x600 placeholder
Russia To Bail Out Trust Bank
Russia's economic and currency crisis has claimed its largest banking casualty to date, after the central bank said it will bail out private lender Trust Bank.
More Top Equities Stories Of The Day
Taiwan November Export Orders Stay Near Record High -- Update
Whistleblowers Score a Big Payday -- Update
Repsol to Buy Talisman Energy for $8.3 Billion --Update
China Industrial Output Likely to Grow 8.3% This Year, Official Says
Mobile's Rise Poses a Riddle for Banks
U.S. Hot Stocks: Hot Stocks to Watch
Brazilian Shares Rise, Led by Rossi Residencial; Real Weakens Slightly
U.S. Hot Stocks: Hot Stocks to Watch
DewDiligence Member Level  Saturday, 03/15/08 06:12:36 PM
Re: masterlongevity post# 8871
Post # of 19308 
Re: Expiration dates of Rituxan patents

According to DNA itself, the US patents that protect Rituxan are 5,677,180 (“Chimeric antibody with specificity to human B cell surface antigen”) and 5,736,137 (“Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma”).

The ‘180’ patent expires in Oct 2014 and the ‘1378’ patent expires in Apr 2015.

GTC believes that only the ‘180’ patent is relevant to GTC’s CD20 mAb program.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist